The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

Exclusion criteria

• . History of prior allogeneic transplantation
• . Cardiac disease: symptomatic congestive heart failure or evidence of left ventricular dysfunction (Ejection fraction \< 50%) as measured by gated radionuclide ventriculogram or echocardiogram; active angina pectoris, or uncontrolled hypertension; history of myocardial infarction with depressed ejection fraction.
• . Pulmonary disease: symptomatic chronic obstructive lung disease, symptomatic restrictive lung disease, or corrected diffusing capacity for carbon monoxide (DLCO) of \< 50% of predicted, corrected for hemoglobin.
• . Renal disease: serum creatinine \> 2.0 mg/dl and calculated creatinine clearance \< 40 mL/min.
• . Hepatic disease: serum bilirubin \> 2.0 mg/dl (except in the case of Gilbert's syndrome or ongoing hemolytic anemia), aspartate aminotransferase (SGOT) or alanine aminotransferase (SGPT) \> 5 × upper limit of normal.
• . Neurologic disease: symptomatic leukoencephalopathy, active central nervous system (CNS) malignancy or other neuropsychiatric abnormalities believed to preclude transplantation.
• . HIV antibody.
• . Uncontrolled infection.